Eurofins Scientific will help Adial validate a companion diagnostic for a drug being developed and identify patients for enrollment into a Phase III trial.
The addition of the Y chromosome detection will enable the firm to refine its already-approved MaternalFetalScreen T1 test to provide personalized risk assessment.
The New York Times reports that researchers are working on a forensic DNA test to tell identical twins apart.
Eurofins will distribute Synthego's sgRNA products to its customers in 44 countries.
The test is based on the company's GARD platform for measuring genetic biomarkers of immune reactions to predict chemical sensitivities.
The system combines sample preparation technology capable of amplifying tens of thousands of locations in the genome with next-generation sequencing.
Genoma, which is based in Italy, offers a wide range of specialty diagnostics services with an emphasis on noninvasive prenatal testing, as well as oncology tests.
An OpenArray panel designed to simultaneously test for 17 viruses and 13 bacteria and protozoa was able to detect pathogens from human blood donor samples with an accuracy of about 95 percent.
The deal will close in July and will expand Eurofins' capabilities in areas including DNA sequencing and genetic testing.
The deal is expected to expand Eurofin's clinical diagnostic footprint in Europe.
US National Institutes of Health Director Francis Collins says he will avoid male-only speaker panels.
Two patients fell ill, and one subsequently died, following a fecal microbiome transplant that harbored multi-drug-resistant bacteria, according to the New York Times.
Technology Review reports that eGenesis is testing whether organs from genetically modified pigs can be transplanted into monkeys.
In Science this week: almond reference genome, and more.